Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer to Drive Global Growth

Alvotech, a leading biotech firm specializing in biosimilar medicines, has announced the appointment of Dr. Balaji V. Prasad as its new Chief Strategy Officer. With 25 years of experience spanning medicine, consulting, and financial analysis, Dr. Prasad has closely followed Alvotech’s growth and brings deep expertise in specialty pharmaceuticals and healthcare investment. Most recently, he served as a director and top-ranked equities analyst at Barclays, covering US specialty pharma, and has held leadership roles at Goldman Sachs and a Swiss asset management firm.

Chairman and CEO Róbert Wessman expressed confidence in Dr. Prasad’s ability to accelerate Alvotech’s strategic growth, citing his deep industry knowledge and investment community ties. Dr. Prasad, a medical doctor by training, emphasized the critical role of biosimilars in expanding access to essential medicines worldwide. He looks forward to leveraging his diverse expertise to strengthen Alvotech’s position as a global leader in affordable biologics, ensuring both patient access and investor value.